Clinical trials: Clotting Disorder
Immune Thrombocytopenic Purpura
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
- Trial name
- ITP (NCT02273960)
- Testing
- BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Immune Thrombocytopenia, Treatment
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of primary immune thrombocytopenia in patients who have failed first-line treatment.
- Trial name
- NCT06838962
- Testing
- Daratumumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hemophilia B, Blood Coagulation Disorders, Inherited
AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)
Freeline is developing adeno-associated virus (AAV) vector based gene therapies for a number of diseases and is actively advancing a programme in Haemophilia B (HB).
- Conditions
- Hemophilia B, Blood Coagulation Disorders, Inherited, Blood Coagulation Disorder, Haematologic Disease
- Trial name
- ECLIPSE (NCT04272554)
- Where
- 56 sites in United States, Australia and 10 more
- Volunteers
- 37 people
- Sponsor
- Spur Therapeutics
Blood Coagulation
Safety of Oral Anticoagulants Registry
The goal of SOAR is to characterize the clinical and economic impact of clinicians' responses to major bleeding complications and pre-procedural concerns for bleeding risk in patients treated with oral anticoagulants (warfarin…
- Trial name
- SOAR (NCT02745054)
- Testing
- mgt of bleeding concerns/complications of oral anticoagulants
- Where
- 9 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Hospital Quality Foundation
Hemophilia A
A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a…
- Trial name
- A-MORE (NCT04293523)
- Testing
- ELOCTA
- Where
- 53 sites in Czechia, Estonia and 12 more
- Volunteers
- 427 people
- Sponsor
- Swedish Orphan Biovitrum
Ecchymosis and Erythema Commonly Associated With Soft Tissue Filler Injections
A Study of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures
Nutritional supplementation is more effective than placebo in the reduction of redness and bruising following facial ablative laser resurfacing treatments and following soft tissue filler injections to the lips and/or malar areas.
- Trial name
- NCT01919359
- Testing
- Multizyme Cellular Vitality Cyruta Plus SHEP
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- DeNova Research
Coagulation Disorder
QStat Pilot Reference Range Study
The objective is to determine the initial reference range intervals for the parameters reported by the Quantra System with the QStat Cartridge.
- Trial name
- NCT04490759
- Testing
- Quantra System
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- HemoSonics LLC
Multifocal Lymphangioendotheliomatosis With Thrombocytopenia, Cutaneovisceral Angiomatosis With Thrombocytopenia
Registry for Vascular Anomalies Associated With Coagulopathy
PURPOSE The purpose of this study is to learn more about multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT). MLT is a rare vascular disorder characterized by multiple congenital skin and visceral lesions, profound…
- Conditions
- Multifocal Lymphangioendotheliomatosis With Thrombocytopenia, Cutaneovisceral Angiomatosis With Thrombocytopenia, Vascular Anomaly With Thrombocytopenia, Hemangiomas
- Trial name
- VAC (NCT00576888)
- Testing
- no intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Hemophilia A
ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
The purpose of the study is to document the natural history of hemophilia A disease and long-term outcomes in terms of effectiveness, safety and quality of life in participants receiving Antihemophilic Factor (Recombinant) …
- Trial name
- AHEAD (NCT02078427)
- Testing
- ADVATE, ADYNOVI
- Where
- 110 sites in Australia, Austria and 20 more
- Volunteers
- 951 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A
Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
Most transient inhibitor formation, if any, will develop within the first 4 weeks. The study is to further monitor whether participants with severe Hemophilia A will develop inhibitors or antibodies at the later stage when…
- Trial name
- NCT00621673
- Testing
- Kogenate (BAY 14-2222)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Acute on Chronic Liver Failure
Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and Sepsis
This study attempts to clarify the pathophysiology of haemostasis and haematopoiesis in relation to the evidence of sepsis in liver disease, and compares the accuracy of various available laboratory tests in assessment of these…
- Trial name
- NCT02307409
- Testing
- Sonoclot/TEG test
- Where
- India
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
Acquired Bleeding Disorder, Cirrhosis
Use of NovoSeven® in Active Variceal Bleeding
This trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.
- Trial name
- NCT00154492
- Testing
- activated recombinant human factor VII
- Where
- 44 sites in Austria, Czechia and 10 more
- Volunteers
- 265 people
- Sponsor
- Novo Nordisk A/S
Severe Hemophilia A
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
The purpose of the study is to collect long-term data on the inhibitor development rate of Human-cl rhFVIII in previously untreated patients with severe Hemophilia A.
- Trial name
- NCT01992549
- Testing
- Human-cl rhFVIII
- Where
- 15 sites in United States, Canada and 7 more
- Volunteers
- 48 people
- Sponsor
- Octapharma
Blood Coagulation Disorders, Trauma
Evaluating URMC's Massive Transfusion Protocol
The purpose of the study is to evaluate the efficacy of the University of Rochester Medical Center's current Massive Transfusion Protocol.
- Conditions
- Blood Coagulation Disorders, Trauma, Acute Coagulopathy
- Trial name
- MTP-TEG (NCT02083549)
- Testing
- Blood collection
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Rochester
Chronic Subdural Hematoma
Template-Guided Burr-Hole Drainage With Middle Meningeal Artery Coagulation for Chronic Subdural Hematoma
Chronic subdural hematoma is a collection of blood and fluid on the surface of the brain that is common in older adults. Burr-hole drainage is a standard surgical treatment, but the hematoma may come back in some patients and…
- Trial name
- 3D-MMA-cSDH Tr (NCT07720687)
- Testing
- Standard Burr-Hole Drainage Group, 3D-Printed Template-Guided Burr-Hole Drainage With Attempted MMA Coagulation Group
- Where
- China
- Volunteers
- 440 people
- Sponsor
- The Second Hospital of Anhui Medical University
Disseminated Intravascular Coagulation
The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation
The project was undertaking by Qilu Hospital of Shandong University, aiming to evaluate diagnostic performance of hemostatic biomarkers in disseminated intravascular coagulation.
- Trial name
- NCT05995093
- Testing
- no intervention
- Where
- China
- Volunteers
- 462 people
- Sponsor
- Qilu Hospital of Shandong University
Hemophilia A
BAX 855 Continuation
To continue the evaluation of the safety and efficacy of BAX 855 for prophylaxis and treatment of bleeding episodes in adult and pediatric previously treated patients (PTPs) aged ≤ 75 years of age with severe hemophilia A.
- Trial name
- NCT01945593
- Testing
- BAX855
- Where
- 89 sites in United States, Australia and 21 more
- Volunteers
- 218 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A Patient
Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A
Recent studies have shown that pharmacokinetic (PK)-guided extended half-life (EHL) factor VIII can improve joint health in patients with hemophilia A.
- Trial name
- NCT07439055
- Testing
- Switching to low dose emicizumab
- Where
- Thailand
- Volunteers
- 18 people
- Sponsor
- Chulalongkorn University
Bleeding Disorder, Von Willebrand Disease (VWD)
The Bleeding Assessment Tool (BAT)
This study looks at whether adding simple family history questions to a standard bleeding questionnaire can better identify children who truly have mild bleeding disorders.
- Trial name
- BAT Protocol (NCT07560007)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
IgAN, IgAVN
Study of Ravulizumab in Pediatric Participants With Primary IgAN
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or…
- Conditions
- IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis
- Trial name
- NCT07024563
- Testing
- Ravulizumab
- Where
- 15 sites in United States, China and 5 more
- Volunteers
- 36 people
- Sponsor
- Alexion Pharmaceuticals, Inc.